In this episode, David talks with Victor Acero, co-founder of the psychedelic conference PhilaDelic, to learn about the conference and about the different topics that are expected to be covered by guest speakers during it such as consciousness and mind, law and public policy, and spiritualism, mysticism, and theology, to name a few.
Similar Posts
Can TRYP Therapeutics Treat Chronic Pain and Eating Disorders With Psychedelics? (TRYP / TRYF)
In today’s episode, we’ll be interviewing CEO and Chairman of TRYP Therapeutics, Greg Mckee. Thus far, this is one of the most informative conversations I’ve had the pleasure of having about the psychedelic industry, the different segments that could be simultaneously tackled, the challenges and opportunities for many of the players in this industry and much more.
I hope you stay till the end and are able to get some value from this discussion.
TRYP Therapeutics (CSE: TRYP) (OTC: TRYPF), is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. Some of the diseases TRYP is addressing are: eating disorders and fibromyalgia (chronic widespread pain) .
TRYP intends to seek approval from FDA to proceed directly into a Phase 2 clinical trial based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803.
Timestamps:
0:00 – Intro
0:40 – TRYP’s mission and Greg Mckee’s personal involvement
2:59 – Expanding on TRYP’s main molecules: TRP 8802 and TRP 8803
8:18 – Expanding on TRYP’s flagship programs: Fibromyalgia and Eating Disorder
14:29 – Clinical trial progress and anticipated start of Phase IIa trials
18:26 – Anticipated commercialization timelines
21:34 – TRYP Therapeutics’ competitive advantage
27:22 – Expected relationship with the traditional pharmaceuticals industry and potential partnerships
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Pertinent links:
Tryp Therapeutics’ Mission:
https://tryptherapeutics.com/
Tryp’s pipeline progress:
https://tryptherapeutics.com/pipeline/
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (TRYP) via digital communications. We have been paid ($1000) .
https://tryptherapeutics.com/
CSE: TRYP | OTC: TRYPF
#TRYP #TrypTherapeutics #TrypStock
Removing Barriers of Accessibility to Psychedelics with Brett Waters
Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.
Cathie Wood of Ark Invest Comments on Psychedelic Stocks like MindMed “We DON’T Invest In Binaries”
Will Ark Invest (ARKK) and Cathie Wood invest in MindMed ( MMED / MMEDF/ MMQ) or other Psychedelic Stocks? In this episode, Cathie Wood talks to Kevin O’Leary about the potential for psychedelic stocks and MindMed.
Kevin O’Leary is a BIG bull in MindMed, but what does Cathie Wood think? Will Ark invest in MindMed? Well, no. She is clear that Ark does not invest in binary outcomes, which MMED / MMEDF cleary is.
Having said this, the door may be left open for the future, as ARKK invests in Healthcare companies using artifical intellegence, exactly what MindMed’s Albert division is working on. Also, once clinical trial results come in, MindMed will no longer be a binary choice. SO anything is possible.
I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedNews #PsychedelicStocks
Psychedelic Decriminalization Update : Colorado, Oklahoma & Maine Move To Legalize Psychedelics?
Psychedelic Decriminalization Update Today, we take a look at 3…
MindMed CEO AMA: 18-MC Patent, Digital Tech, LSD Trials and More! (MNMD / MMED)
In today’s episode, James from PSYCBiz interviews Robert Barrow, CEO…